Drugs used in ovulation induction. Safety of patient and offspring.
Data on the safety of agents used to induce ovulation in women are presented, with a special reference to the normality of children at birth and puberty. No overall increase in anomalies has been found after the use of clomiphene citrate. This drug has been given up to day 35 of pregnancy, and its safety in these circumstances requires further analysis. More studies will also be needed on offspring as they pass through puberty, to ensure there are no defects in their Müllerian system. No increase in anomalies has been noted after the use of human menopausal gonadotrophins (HMG). The onset of menstrual rhythms and other parameters in the offspring appear to be normal. No increase in various cancers has been identified following the use of clomiphene or HMG, although most treated women have yet to enter the high risk years.
D006063:Chorionic Gonadotropin / Q000009:adverse effects*; D002996:Clomiphene / Q000009:adverse effects*; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008596:Menotropins / Q000009:adverse effects*; D010062:Ovulation Induction; D011247:Pregnancy; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D012744:Sex Ratio
D006063:Chorionic Gonadotropin; D012738:Sex Hormone-Binding Globulin; D002996:Clomiphene; D004958:Estradiol; D008596:Menotropins